Læknablaðið : fylgirit - 05.01.2015, Qupperneq 95

Læknablaðið : fylgirit - 05.01.2015, Qupperneq 95
X V I I V Í S I N D A R Á Ð S T E F N A H Í F Y L G I R I T 8 2 LÆKNAblaðið/Fylgirit 82 2015/101 95 registry at Landspitali and interviews with patients. The study period was 2009-2013. Discontinuation was categorized into two sets. The first one included cases where treatment was completely discontinued or switched to a different TNFα inhibitor. The second set included cases where treatment was temporarily discontinued (≥ 112 days) and subse- quently resumed with the same TNFα inhibitor. Results: Of the 513 patients that were included in the study, 283 patients discontinued treatment, 229 completely or switched to other drug (304 occasions) and 54 discontinued temporarily their TNFα treatment (74 occasions). The most common reasons for discontinuation of treatment were an inadequate response to treatment (36.2%) and adverse events (32.6%). The latter was also the most common reason for temporal treatment discontinuation (28.4%), infection being the far most common (76.2%). In cases of discontinuation/switch of treatment, infliximab was most commonly discontinued (45.7%) while teatment with etanercept was most commonly temporarily discontinued (64.9%). Conclusions: Inadequate response and adverse events are the most common reasons why RA and PsA patients discontinue TNFα inhibitor treatment and infliximab is the drug that is most commonly discont- inued. However when patients temporarily stop treatment, infection is the main reason and the drug most commonly involved is etanercept. V 122 Fóðrun heilgóma Ævar Pétursson, Svend Richter Tannlæknadeild Háskóla Íslands aevarp@gmail.com Inngangur: Oft er hægt að fóðra eldri heilgóma í stað endursmíði þeirra. Fóðrun heilgóma er því snar þáttur í heilgómagerð. Engar rannsóknir hafa verið gerðar hér á landi til að skoða starfshætti tannlækna og tann- smiða við fóðrun, samvinnu þessara stétta og hvort framkvæmd fóðr- unar standist þær kröfur sem gerðar eru hér nú. Efniviður og aðferðir: Spurningalisti var sendur tannlæknum í Tannlæknafélagi Íslands og 20 tannsmiðum í Tannsmiðafélag Íslands sem valdir voru af handahófi. Notast var við megindlega aðferðafræði. Gagnaúrvinnsla var unnin á SurveyMonkey® og Excel (Microsoft Corporation). Niðurstöður: Af 284 tannlæknum svöruðu 134 (47,2%) en allir tann- smiðir (100%). 90,1% tannlækna starfa við heilgómagerð. 45% tannsmiða notar alltaf kaldhert plast við fóðrun, 15% stundum en 20% aldrei. Þetta er óháð óska meirihluta tannlækna að fóðrun sé gerð samdægurs (alltaf 66,7%, oft 21,1%). Flestir tannlækna segjast gefa tannsmiðum leiðbein- ingar um hönnun afturmarka efri heilgóms en tannsmiðir kannast ekki við það. Langalgengasta mátefni var Xantopren (50,0%) en næst komu President og Impregum (12,5% hvort). Compound var algengast til mótunar brúna (60,7%). 8,1 % tannlækna fræsir ekki af brúnum og mótar á ný við fóðrun. Tannlæknar telja að þeir noti relining alltaf eða oft í 78,3% tilfella og tannsmiðir að þeir geri relining í 95,0% tilfella Ályktanir: Tannsmiðir fóðra frekar með kaldfjölliðuðu plasti en hita- fjölliðuðu. Ekki er fylgni á milli þess að tannlæknar vilji að fóðrun sé gerð samdægurs og að tannsmiðir noti kaldfjölliðað plast. Tannlæknum og tannsmiðum ber ekki saman hvor ákveði afturmörk efri heilgóms eða algengi relining á móti rebasing.
Qupperneq 1
Qupperneq 2
Qupperneq 3
Qupperneq 4
Qupperneq 5
Qupperneq 6
Qupperneq 7
Qupperneq 8
Qupperneq 9
Qupperneq 10
Qupperneq 11
Qupperneq 12
Qupperneq 13
Qupperneq 14
Qupperneq 15
Qupperneq 16
Qupperneq 17
Qupperneq 18
Qupperneq 19
Qupperneq 20
Qupperneq 21
Qupperneq 22
Qupperneq 23
Qupperneq 24
Qupperneq 25
Qupperneq 26
Qupperneq 27
Qupperneq 28
Qupperneq 29
Qupperneq 30
Qupperneq 31
Qupperneq 32
Qupperneq 33
Qupperneq 34
Qupperneq 35
Qupperneq 36
Qupperneq 37
Qupperneq 38
Qupperneq 39
Qupperneq 40
Qupperneq 41
Qupperneq 42
Qupperneq 43
Qupperneq 44
Qupperneq 45
Qupperneq 46
Qupperneq 47
Qupperneq 48
Qupperneq 49
Qupperneq 50
Qupperneq 51
Qupperneq 52
Qupperneq 53
Qupperneq 54
Qupperneq 55
Qupperneq 56
Qupperneq 57
Qupperneq 58
Qupperneq 59
Qupperneq 60
Qupperneq 61
Qupperneq 62
Qupperneq 63
Qupperneq 64
Qupperneq 65
Qupperneq 66
Qupperneq 67
Qupperneq 68
Qupperneq 69
Qupperneq 70
Qupperneq 71
Qupperneq 72
Qupperneq 73
Qupperneq 74
Qupperneq 75
Qupperneq 76
Qupperneq 77
Qupperneq 78
Qupperneq 79
Qupperneq 80
Qupperneq 81
Qupperneq 82
Qupperneq 83
Qupperneq 84
Qupperneq 85
Qupperneq 86
Qupperneq 87
Qupperneq 88
Qupperneq 89
Qupperneq 90
Qupperneq 91
Qupperneq 92
Qupperneq 93
Qupperneq 94
Qupperneq 95
Qupperneq 96
Qupperneq 97
Qupperneq 98
Qupperneq 99
Qupperneq 100
Qupperneq 101
Qupperneq 102
Qupperneq 103
Qupperneq 104
Qupperneq 105
Qupperneq 106
Qupperneq 107
Qupperneq 108
Qupperneq 109
Qupperneq 110
Qupperneq 111
Qupperneq 112
Qupperneq 113
Qupperneq 114
Qupperneq 115
Qupperneq 116
Qupperneq 117
Qupperneq 118
Qupperneq 119
Qupperneq 120
Qupperneq 121
Qupperneq 122
Qupperneq 123
Qupperneq 124
Qupperneq 125
Qupperneq 126
Qupperneq 127
Qupperneq 128
Qupperneq 129
Qupperneq 130
Qupperneq 131
Qupperneq 132
Qupperneq 133
Qupperneq 134
Qupperneq 135
Qupperneq 136
Qupperneq 137
Qupperneq 138
Qupperneq 139
Qupperneq 140
Qupperneq 141
Qupperneq 142
Qupperneq 143
Qupperneq 144
Qupperneq 145
Qupperneq 146
Qupperneq 147
Qupperneq 148
Qupperneq 149
Qupperneq 150
Qupperneq 151
Qupperneq 152
Qupperneq 153
Qupperneq 154
Qupperneq 155
Qupperneq 156
Qupperneq 157
Qupperneq 158
Qupperneq 159
Qupperneq 160
Qupperneq 161
Qupperneq 162
Qupperneq 163
Qupperneq 164
Qupperneq 165
Qupperneq 166
Qupperneq 167
Qupperneq 168
Qupperneq 169
Qupperneq 170
Qupperneq 171
Qupperneq 172
Qupperneq 173

x

Læknablaðið : fylgirit

Direct Links

Hvis du vil linke til denne avis/magasin, skal du bruge disse links:

Link til denne avis/magasin: Læknablaðið : fylgirit
https://timarit.is/publication/991

Link til dette eksemplar:

Link til denne side:

Link til denne artikel:

Venligst ikke link direkte til billeder eller PDfs på Timarit.is, da sådanne webadresser kan ændres uden advarsel. Brug venligst de angivne webadresser for at linke til sitet.